Metformin is associated with reduced COVID-19 severity in patients with prediabetes.

ABSTRACT:

Aims

Studies suggest that metformin is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemics. We assessed if metformin is associated with reduced incidence of severe COVID-19 for patients with prediabetes or polycystic ovary syndrome (PCOS), common diseases that increase the risk of severe COVID-19.

Methods

This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls). After balancing via inverse probability score weighting, associations with COVID-19 severity were assessed by logistic regression.

Results

In the prediabetes cohort, when compared to levothyroxine, metformin was associated with

SUBMITTER: Chan LE 

PROVIDER: S-EPMC9663381 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature